Cencora, Inc. (NYSE:COR) Shares Bought by Aviso Financial Inc.

Aviso Financial Inc. raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 21.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,464 shares of the company's stock after buying an additional 1,305 shares during the period. Aviso Financial Inc.'s holdings in Cencora were worth $1,677,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in COR. Hickory Asset Management Inc. acquired a new stake in Cencora during the 4th quarter worth $572,000. Sylvest Advisors LLC purchased a new position in shares of Cencora during the fourth quarter worth about $1,105,000. Insight Wealth Strategies LLC increased its position in Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after acquiring an additional 11,232 shares during the period. Cerity Partners LLC raised its stake in Cencora by 10.1% during the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock valued at $8,881,000 after acquiring an additional 3,610 shares during the last quarter. Finally, Vontobel Holding Ltd. lifted its position in Cencora by 46.9% during the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after acquiring an additional 1,995 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently commented on COR shares. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company increased their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday. JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price for the company. Finally, Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $280.20.

Remove Ads

Cencora Price Performance

Shares of Cencora stock traded up $3.06 during trading on Tuesday, hitting $264.02. 1,745,536 shares of the company were exchanged, compared to its average volume of 1,353,205. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $265.36. The stock has a market capitalization of $51.20 billion, a price-to-earnings ratio of 37.56, a P/E/G ratio of 1.31 and a beta of 0.51. The firm has a 50 day moving average price of $248.23 and a 200 day moving average price of $239.31. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.83%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 13,648 shares of company stock worth $3,382,462. Insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.